Hester C, et al. - The role of adjuvant therapy (AT) in resected distal cholangiocarcinoma (dCCA) was determined and subgroups that benefit from AT were identified via retrospectively reviewing surgically resected dCCA in the NCDB from 2004 to 2013. They identified 1782 patients who underwent dCCA resection, among these, 840 (47%) were in the observation group and 942 (53%) received AT. Outcomes revealed improved OS in association with AT reception in resected dCCA, especially in T3/T4 tumors, node positive disease, and positive margins.